# AstraZeneca Signs $1.5B Licensing Deal for Dizal Lung Cancer Drug

> partnership · REPORTED · 2026-07-01

In July 2026, AstraZeneca struck a $1.5 billion licensing agreement with Dizal for a lung cancer drug candidate, following a separate $200 million COPD licensing deal from Chia Tai Tianqing days earlier, reflecting a broader industry surge in outbound licensing from Chinese biotechs.

About AstraZeneca: AstraZeneca is a global biopharmaceutical company with a leading oncology portfolio including Tagrisso and Imfinzi, and a major presence in cardiovascular, respiratory, and rare disease therapeutics.

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://www.emjreviews.com/emj-gold/news/month-in-pharma-news-explained-july/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.